EUR 23.6
(1.72%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 15.7 Million EUR | -46.89% |
2022 | 29.56 Million EUR | 425.8% |
2021 | -9.07 Million EUR | 87.22% |
2020 | -71.01 Million EUR | -713.52% |
2019 | 11.57 Million EUR | -73.53% |
2018 | 43.72 Million EUR | 32.27% |
2017 | 33.05 Million EUR | 318.89% |
2016 | 7.89 Million EUR | 150.62% |
2015 | 3.14 Million EUR | -71.14% |
2014 | 10.91 Million EUR | -12.58% |
2013 | 12.48 Million EUR | -42.94% |
2012 | 21.87 Million EUR | 105.63% |
2011 | 10.63 Million EUR | 2.34% |
2010 | 10.39 Million EUR | 69.12% |
2009 | 6.14 Million EUR | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | 75.74 Million EUR | 0.0% |
2023 FY | 15.7 Million EUR | -46.89% |
2023 Q4 | 46.79 Million EUR | 0.0% |
2023 Q2 | -15.59 Million EUR | 0.0% |
2022 Q4 | 66.06 Million EUR | 0.0% |
2022 FY | 29.56 Million EUR | 425.8% |
2022 Q2 | -35.99 Million EUR | 0.0% |
2021 Q2 | 23.45 Million EUR | 0.0% |
2021 FY | -9.07 Million EUR | 87.22% |
2021 Q4 | -32.41 Million EUR | 0.0% |
2020 Q2 | -32.65 Million EUR | 0.0% |
2020 Q4 | -37.72 Million EUR | 0.0% |
2020 FY | -71.01 Million EUR | -713.52% |
2019 Q2 | -18.4 Million EUR | 0.0% |
2019 FY | 11.57 Million EUR | -73.53% |
2019 Q4 | 29.31 Million EUR | 0.0% |
2018 Q4 | -13.6 Million EUR | 0.0% |
2018 FY | 43.72 Million EUR | 32.27% |
2018 Q2 | 57.33 Million EUR | 0.0% |
2017 Q2 | 7.08 Million EUR | 0.0% |
2017 FY | 33.05 Million EUR | 318.89% |
2017 Q4 | 25.97 Million EUR | 0.0% |
2016 Q4 | 9.39 Million EUR | 0.0% |
2016 FY | 7.89 Million EUR | 150.62% |
2016 Q2 | -1.5 Million EUR | 0.0% |
2015 Q4 | 8.02 Million EUR | 0.0% |
2015 Q2 | 5.1 Million EUR | 0.0% |
2015 FY | 3.14 Million EUR | -71.14% |
2014 FY | 10.91 Million EUR | -12.58% |
2014 Q2 | 6.18 Million EUR | 0.0% |
2014 Q4 | 4.73 Million EUR | 0.0% |
2013 FY | 12.48 Million EUR | -42.94% |
2013 Q4 | 6.8 Million EUR | 0.0% |
2013 Q2 | 5.67 Million EUR | 0.0% |
2012 Q4 | 2.21 Million EUR | 0.0% |
2012 Q2 | 5.32 Million EUR | -0.0% |
2012 Q1 | 5.32 Million EUR | 0.0% |
2012 FY | 21.87 Million EUR | 105.63% |
2012 Q3 | 2.21 Million EUR | -58.35% |
2011 FY | 10.63 Million EUR | 2.34% |
2010 FY | 10.39 Million EUR | 69.12% |
2009 FY | 6.14 Million EUR | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Apontis Pharma AG | -15.1 Million EUR | 203.974% |
Dermapharm Holding SE | 182.89 Million EUR | 91.416% |
Evotec SE | -47.5 Million EUR | 133.048% |
MERCK Kommanditgesellschaft auf Aktien | 3.6 Billion EUR | 99.565% |
PharmaSGP Holding SE | 40.91 Million EUR | 61.627% |
SynBiotic SE | -7.58 Million EUR | 307.071% |